|Bid||117.52 x 800|
|Ask||118.49 x 800|
|Day's Range||117.59 - 118.87|
|52 Week Range||81.05 - 128.54|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||37.13|
|Forward Dividend & Yield||1.80 (1.53%)|
|Ex-Dividend Date||Apr 14, 2021|
|1y Target Est||N/A|
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2021.
Efforts to ramp up COVID-19 testing capacity in the Philippines have received fresh impetus, with the Office of the Civil Defense (OCD) procuring and distributing the Abbott Panbio™ COVID-19 Ag Rapid Test Device for the detection of the SARS-CoV-2 virus in people suspected of having COVID-19. The procurement of 500,000 Panbio rapid antigen tests is part of the OCD's COVID-19 response to the pandemic and is in addition to purchases by LGUs (Local Government Units) to meet local testing needs. Forty-five hospitals and LGUs in Metro Manila and nearby provinces recently received these tests procured by the OCD.
Abbott (NYSE: ABT) announced today it began shipping its BinaxNOW™ COVID-19 Ag Self Test to retailers across the country. Consumers can expect the test to be available in the next few days online and in some stores. Broader nationwide availability is expected in the next two weeks as tests work their way through distribution channels.